---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096204"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:46.579407+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics Q2 net loss $20.0M; cash $312.4M; pipeline advances with ELVN-001/002 dosing starts

## Summary
- Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.
- Q2 2024 net loss $20.0M ($16.7M Q2 2023); R&D expense $18.8M ($15.2M), G&A $5.8M ($5.0M).
- ELVN-001 Phase 1b arm dosing initiated in CML patients; abstract accepted for September ESH-iCMLf conference.
- ELVN-002 Phase 1a combo trial with trastuzumab +/- chemo and exploratory arm with Kadcyla dosed first patients.
- Phase 1 data for ELVN-001 and initial ELVN-002 combo data expected in 2025.

## SEC filing metadata
- accession: 0000950170-24-096204
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000095017024096204/0000950170-24-096204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000095017024096204/elvn-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096204
- JSON: https://secwatch.observer/filing/0000950170-24-096204.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.